Rx-360 Establishes Asia Working Group - India
Rx-360, an international, non-profit supply chain consortium, has announced, the formation of the Rx-360 Asia Working Group – India. The Working Group will be led by Anish Swadi, Vice President, Business Development at Hikal, Huzefa Hussain, Manager-Quality Assurance at Amgen, and Prashant Wani, Senior Supplier Auditor at Eli Lilly & Company. The Working Group held an initial face-to-face meeting in Mumbai, India on 24 February 2015. Meeting attendees were from global and local India pharmaceutical and supplier companies.
The Rx-360 Working Group - Asia has had a vibrant group in Shanghai for almost 2 years. Given the size of India’s pharma market and its importance as a manufacturer and exporter of APIs and drug product to North America and Europe, Rx-360 believed it was important to also develop a presence in India.
The Working Group will focus its attention on identifying and mitigating root causes of quality problems and supply chain security. As a neutral, open, and consensus building industry forum, Rx-360 seeks to help address these quality challenges and support India industry.
The Working Group's goals are to
• build Rx-360’s reputation and credibility in India as a group with tools to solve problems relevant to the global pharma industry and supply chain
• help understand and mitigate root causes of the most pressing quality challenges
• share best practices and case studies from sites
• spread awareness and understanding about Rx-360, its activities, and its audit programs, in India among India-based suppliers and manufacturers
• position Rx-360 as a mentoring resource for the India pharma industry.
The Rx-360 India Working Group has prepared a survey to solicit feedback from individuals who may have encountered data integrity (DI) issues in the course of their work in GMP sites located in India. The purpose of this survey is to benchmark experiences and mitigation strategies. The survey is voluntary, confidential and anonymous. Results of the survey will be shared individually with participating companies. The intent of the survey is to gather benchmarking information to develop educational materials and other efforts that can help to advance data integrity understanding and mitigations.
To access the survey, please click here
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.